Current Research Studies

Cancer - PLAT-01: A Phase I Feasibility and Safety Study of Cellular Immunotherapy for Relapsed/Refractory Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced to Express a CD19-Specific Chimeric Antigen Receptor

Condition or Therapy:

B cell Leukemia


Cancer and blood disorders

What is the goal of this study?

The goal of this study is to understand how the personal body can use its own T cells to recognize CD19, a protein that is present on cancer cells.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are 1 to 26 years old and 
  • Have CD19+ leukemia in a relapse

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Rebecca Gardner